Please Wait...

Quality Assurance

Bioclinica Laboratory is committed to providing clients with reliable and reproducible analytical methods for biomarkers while safeguarding patient care and achieving the highest standards in laboratory quality. Using a convergence of analytic pre-study and in-study validation across a wide range of assay formats, we deliver biomarker feasibility assessments and evaluation in a regulatory compliant environment. Our rigorous quality control combined with our experienced laboratory services translates into efficient analysis of biological samples from your clinical trials. All of Bioclinica Lab's procedures and training programs comply with current regulatory requirements.

Our key business operations are governed by a comprehensive Quality Management System implemented to reflect industry standards and best practices for study management, software development, IT infrastructure management, documentation, QC assessments, training, and CAPA.

The Molecular Markers Database System (MMDS)
The Molecular Markers Database System (MMDS) was developed by Bioclinica Lab for handling clinical trial data, from sample information through data analysis and transfer. The MMDS, based on an Oracle database and fully 21 CFR Part 11 compliant, supports each new study and provides a consistent user interface, regardless of the size or complexity of the clinical protocol. It has components for study team members to perform protocol information entry, sample receipt, data query, analysis, reporting, and other functions related to study data. Our analytical instruments and automated platforms are connected to the MMDS, and our data security procedures assure integrity, protection and backup of study data. Bioclinica Lab has a dedicated IT department that is responsible for the development, improvement, maintenance and validation of the MMDS.

As part of validation and QC, Bioclinica Lab regularly participates in Proficiency Testing of molecular markers by the College of American Pathologists (CAP) and the UK National External Quality Assessment Service (UK NEQAS). We continuously monitor and improve our quality to be in compliance with current regulatory guidelines.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Our Medical Imaging team is in the spotlight for a job well done! https://t.co/fkmt0zvPhf https://t.co/D7YMTeiSd3
bioclinica (2 days ago)
RT @melfass: "What this agreement means is that we can allocate scarce resources to areas of higher risk" @US_FDA on MRA with @EMA_News at…
bioclinica (3 days ago)
RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (5 days ago)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (5 days ago)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (5 days ago)
Innovation Theater Kristin Mauri of @bioclinica presenting on RBM & TQM @DrugInfoAssn #DIA2017 https://t.co/zsGroQcpiU
bioclinica (5 days ago)

Latest Blogs: